Navigation Links
Thomas Jefferson University and hospitals tasked to find new radiation drugs
Date:5/4/2011

PHILADELPHIAShortly before Japan's devastating nuclear incident, researchers at Thomas Jefferson University and Hospitals (embed this link to "Hospitals" http://www.jeffersonhospital.org/) received an award to find novel drugs to treat people exposed to dangerous amounts of radiation in the wake of a nuclear terrorist attack or a nuclear accident.

Although a coincidence, the timing and the awards, given to six institutions under the National Institute of Allergy and Infectious Disease's Centers for Countermeasures Against Radiation (CMCR) program, further highlighted the pressing need for new types of drugs.

"The incident in Japan made me realize just how important and pertinent this work is," said lead researcher Ulrich Rodeck, M.D., Ph.D., a professor in the Department of Dermatology and Cutaneous Biology at Jefferson Medical College at Thomas Jefferson University, whose team received $75,000 for the pilot project that builds on six years of research. "We're taking the next step to develop better drugs to help mitigate damage from high exposure to radiation."

Dr. Rodeck, along with Adam P. Dicker, M.D, Ph.D., professor and chairman of the Department of Radiation Oncology at Jefferson, has been working on testing new drugs for radiation exposure in zebrafish since 2004. While their primary aim has been to identify compounds that could be useful in cancer treatments by protecting normal tissue against the harmful effects of radiation therapy, the research serves another purpose.

"On the one hand it could help protect the cancer patient who is treated with radiation, while on the other it may help to alleviate the kind of problems that we see right now unfolding in Japan," said Dr. Rodeck.

The work being done at Jefferson is part of a major research effort to develop medical products to diagnose, prevent and treat the short- and long-term consequences of radiation exposure that's supported by the NIH's National Institute of Allergy and Infectious Disease's CMCR program.

Only seven institutions have been tasked with this charge. Thomas Jefferson University researchers are working with Chandan Guha, M.D., Ph.D, who is the principal investigator of the new CMCR recently established at Albert Einstein Medical Center in New York, one of the institutions chosen.

Their effort builds on the use of zebrafish to study molecular mechanisms of damage by radiotherapy. Dr. Dicker's laboratory program uses this model organism in conjunction with nanotechnology drugs to identify novel radiation protectors and mitigators. This latest project will take the research into mice.

The proposed experiments focus on using small molecule agents that can be taken orally and stockpiled for quick access.

"The drugs we are working on would be of potential benefit to the workers who had to go in and repair the reactor or anyone in close proximity to a disaster of this kind," Dr. Rodeck said.


'/>"/>

Contact: Steve Graff
stephen.graff@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert  

Related medicine news :

1. Thomas Kipps receives ACGT Investigator Award
2. Thomas Jefferson University professor elected AAAS Fellow
3. Gala honors County Supervisor Mark Ridley-Thomas and businesswoman Anne-Merelie Murrell
4. Nationally Renowned Knee Specialist Dr. Thomas Meade Joins Coordinated Health
5. Thomas E. Heftler Migraine Research Award
6. Life Coach and Author Thomas Finn's Highly Anticipated Book, 'A Better Tomorrow- Affirmations and Visualizations the Keys to Success,' Debuts June 15
7. Thomas E. Mower Makes Generous Donations To Primary Children's Medical Center
8. Thomas E. Mower And Karl Malone Instrumental To Success Of Sportsmen For Fish And Wildlife Organization
9. Leading Orthopaedic Surgeon and Regenerative Medical Authority Dr. Thomas A. Einhorn Advances Adult Stem Cell Therapy To Eliminate Hip Replacement Surgery
10. Thomas J. Kent Jr. FDP Capital, LLC Chairman and Former NFL Player Jack Brewer Join Forces
11. Jenesse Salutes Husband and Wife Team, Supervisor Mark Ridley-Thomas and Avis Ridley-Thomas as 2010 Silver Rose Honorees
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Thomas Jefferson University and hospitals tasked to find new radiation drugs
(Date:7/21/2017)... ... July 21, 2017 , ... ... students improve their chances of acceptance to a residency in a United States ... earned degrees outside the U.S. , According to data released by the ECFMG®, ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased ... Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network ... experience in dermatology, skin cancer , and more. She graduated from the University ...
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and ... the rise, say researchers presenting their work at the American Orthopaedic Society ... combination of evaluating the patterns of change in concussion symptom presentation, diagnostic tools ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) is ... rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem ... With such a challenging diagnosis that requires immediate action, patients and caregivers ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing ... specially designed to accommodate patients with a wide range of ailments or special needs, ... has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... 11, 2017  The global market for liquid biopsy ... $394.1 million in 2016.  Although in early stages, the ... in particular as a result of the gradual shift ... recent introduction of a significant number of new liquid ... of tumor biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... July 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... Drug Administration (FDA) has agreed to schedule an End-of-Phase ... IIb trial of its oral insulin capsule ORMD-0801 in ... trial met primary and secondary endpoints by indicating a ...
Breaking Medicine Technology: